Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.
暂无分享,去创建一个
Yaping Li | Qi Yin | Zhiwen Zhang | Yu Chen | Jianlin Shi | Yu Gao | Xinyu He | X. Ji
[1] C. Chu,et al. Reversible pore-structure evolution in hollow silica nanocapsules: large pores for siRNA delivery and nanoparticle collecting. , 2011, Small.
[2] Dong Chen,et al. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. , 2011, ACS nano.
[3] Z. Su,et al. Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy , 2011 .
[4] Rui L. Reis,et al. Controlled Delivery Systems: From Pharmaceuticals to Cells and Genes , 2011, Pharmaceutical Research.
[5] S. Sahoo,et al. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. , 2011, Advanced drug delivery reviews.
[6] Xinglu Huang,et al. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. , 2011, Biomaterials.
[7] K. Singh,et al. Liposome-mesoporous silica nanoparticles fused cores: a safer mode of drug carrier. , 2011, Journal of biomedical nanotechnology.
[8] Yaping Li,et al. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. , 2011, Biomaterials.
[9] Feng Chen,et al. Multifunctional Mesoporous Nanoellipsoids for Biological Bimodal Imaging and Magnetically Targeted Delivery of Anticancer Drugs , 2011 .
[10] Edouard C. Nice,et al. Bypassing Multidrug Resistance in Cancer Cells with Biodegradable Polymer Capsules , 2010, Advanced materials.
[11] Dong Chen,et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. , 2010, ACS nano.
[12] Yu Chen,et al. Core/shell structured hollow mesoporous nanocapsules: a potential platform for simultaneous cell imaging and anticancer drug delivery. , 2010, ACS nano.
[13] Zongxi Li,et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.
[14] C. Dubernet,et al. Folic acid-targeted mesoporous silica nanoparticles for two-photon fluorescence. , 2010, Journal of biomedical nanotechnology.
[15] Liang Zhao,et al. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. , 2010, ACS nano.
[16] Juan L. Vivero-Escoto,et al. Tuning the cellular uptake and cytotoxicity properties of oligonucleotide intercalator-functionalized mesoporous silica nanoparticles with human cervical cancer cells HeLa. , 2010, Biomaterials.
[17] Feng Chen,et al. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. , 2010, ACS nano.
[18] Paul C. Wang,et al. Circumventing tumor resistance to chemotherapy by nanotechnology. , 2010, Methods in molecular biology.
[19] Yong-soo Lee,et al. Doxorubicin Exerts Cytotoxic Effects through Cell Cycle Arrest and Fas-Mediated Cell Death , 2009, Pharmacology.
[20] Yuquan Wei,et al. Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. , 2009, The journal of physical chemistry. B.
[21] M. S. Muthu,et al. Stimulus-responsive targeted nanomicelles for effective cancer therapy. , 2009, Nanomedicine.
[22] F. Gao,et al. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells , 2009, International journal of nanomedicine.
[23] J. Samitier,et al. Stem cell differentiation by functionalized micro- and nanostructured surfaces. , 2009, Nanomedicine.
[24] De-gang Fu,et al. Effect of surface chemistry modification of functional gold nanoparticles on the drug accumulation of cancer cells. , 2008, Journal of biomedical materials research. Part A.
[25] P. Couvreur,et al. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[26] Victor S-Y Lin,et al. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. , 2007, Journal of the American Chemical Society.
[27] Cato T Laurencin,et al. Polymeric nanofibers as novel carriers for the delivery of therapeutic molecules. , 2006, Journal of nanoscience and nanotechnology.
[28] S. Qiu,et al. A controlled release of ibuprofen by systematically tailoring the morphology of mesoporous silica materials , 2006 .
[29] Shilun Qiu,et al. Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica , 2006 .
[30] E. Ho,et al. Regulation of multidrug resistance by pro-inflammatory cytokines. , 2006, Current cancer drug targets.
[31] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[32] B. Aggarwal,et al. Role of chemopreventive agents in cancer therapy. , 2004, Cancer letters.
[33] D. Lake,et al. High-dose chemotherapy in breast cancer. , 2004, Drugs.
[34] Deenu Kanjickal,et al. Modeling of drug release from polymeric delivery systems--a review. , 2004, Critical reviews in therapeutic drug carrier systems.
[35] H. Coley,et al. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.
[36] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[37] 이병준,et al. Poly(ε-caprolactone)-Poly(ethylene glycol)-Poly(ε-caprolactone) 블록 공중합체의 물리적 성질 및 열적 성질에 관한 연구 , 2001 .
[38] L. Mayer,et al. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[39] E Harper,et al. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] M. Boroujerdi,et al. Investigation of the relative affinity of doxorubicin for neutral and negatively charged particulate carriers , 1993 .